SCHEMBL9920568

SCHEMBL9920568

c1ccc(-c2ccc(-c3ccccc3)n2-c2ccc3c(c2)-c2cc([Si](c4ccccc4)(c4ccccc4)c4ccccc4)ccc2C3)cc1

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPK1 P28482 2/20 0.33
XBP1 P17861 1/20 0.33
MYC P01106 1/20 0.33
ALDH1A1 P00352 4/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
HSD17B10 Q99714 1/20 0.32
PKM P14618 2/20 0.32
POLB P06746 2/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
HTT P42858 1/20 0.31
SERPINE1 P05121 1/20 0.31
PDPK1 O15530 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL822796 0.87 MYC (0.39) MAPTKDM4EMAPK1XBP1MYC
SCHEMBL10144775 0.85 HPGDS (0.33) MAPK1ALDH1A1MEN1KMT2A
SCHEMBL9920566 0.81 KDM4E (0.41) KDM4E
SCHEMBL9920525 0.81 KDM4E (0.41) KDM4E
SCHEMBL12219219 0.81 KDM4E (0.38) MAPTKDM4EMAPK1ALDH1A1HSD17B10
SCHEMBL12879656 0.81 KDM4E (0.38) MAPTKDM4EMAPK1ALDH1A1HSD17B10
SCHEMBL9920567 0.79 IL1R1 (0.34) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL9920547 0.79 ESR2 (0.50) MAPTKDM4EMAPK1ALDH1A1HSD17B10
SCHEMBL9920554 0.79 MAPK9 (0.47)
SCHEMBL12219147 0.78 KDM4E (0.36) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839140-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS UDC IRELAND LIMITED (IE) 2023-12-05 US disclosed
US-20170025626-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS UDC IRELAND LTD (IE) 2017-01-26 US disclosed
US-9487548-B2 Metal complexes comprising diazabenzimidazolocarbene ligands and the use thereof in OLEDs UDC IRELAND LIMITED (IE) 2016-11-08 US disclosed
US-9458182-B2 Silyl- and heteroatom-substituted compounds selected from carbazoles, dibenzofurans, dibenzothiophenes and dibenzophospholes, and use thereof in organic electronics BASF SE (DE) 2016-10-04 US disclosed
US-20130032766-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOLOCARBENE LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2013-02-07 US disclosed
US-8362246-B2 Bispyrimidines for electronic applications BASF SE (DE) 2013-01-29 US disclosed
US-20120149904-A1 BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS BASF SE (DE) 2012-06-14 US disclosed
US-20120012821-A1 SILYL- AND HETEROATOM-SUBSTITUTED COMPOUNDS SELECTED FROM CARBAZOLES, DIBENZOFURANS, DIBENZOTHIOPHENES AND DIBENZOPHOSPHOLES, AND USE THEREOF IN ORGANIC ELECTRONICS BASF SE (DE) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149904-A1 BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS DPYD, TYMP, TYMS MAPT 1242/4885KDM4E 1622/4885MAPK1 2604/4885
US-20130032766-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOLOCARBENE LIGANDS AND THE USE THEREOF IN OLEDS OCIAD1, OCIAD2, DRD2 MAPT 883/4885KDM4E 4587/4885MAPK1 2887/4885
US-11839140-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS OCIAD1, OCIAD2, DRD2 MAPT 893/4885KDM4E 4573/4885MAPK1 2918/4885
US-20170025626-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS OCIAD1, OCIAD2, DRD2 MAPT 893/4885KDM4E 4573/4885MAPK1 2918/4885
US-20120012821-A1 SILYL- AND HETEROATOM-SUBSTITUTED COMPOUNDS SELECTED FROM CARBAZOLES, DIBENZOFURANS, DIBENZOTHIOPHENES AND DIBENZOPHOSPHOLES, AND USE THEREOF IN ORGANIC ELECTRONICS DDT, CDKL1, CDK2 MAPT 1784/4885KDM4E 2857/4885MAPK1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.